Medpace Holdings Inc (MEDP) FinancialsMEDPMedpace Holdings Inc

Medpace Holdings, Inc. (MEDP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Metabolic, accounting for 33.6% of total sales, equivalent to $237.56M. Other significant revenue streams include Oncology and Other. Understanding this composition is critical for investors evaluating how MEDP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Medpace Holdings, Inc. maintains a gross margin of 27.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.76%, while the net margin is 17.16%. These profitability ratios, combined with a Return on Equity (ROE) of 162.15%, provide a clear picture of how effectively MEDP converts its operational activities into shareholder value.

In the context of the broader market, MEDP competes directly with industry leaders such as ROL and WSE. With a market capitalization of $16.15B, it holds a significant position in the sector. When comparing efficiency, MEDP's gross margin of 27.56% stands against ROL's 49.73% and WSE's 79.11%. Such benchmarking helps identify whether Medpace Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Medpace reported a trailing twelve-month revenue of $2.8 billion and a net income of $491.5 million, demonstrating strong financial health. The gross margin is currently at 27.56%, which shows a slight decline but remains healthy overall.